Therapeutic applications of hyaluronan

被引：82

作者：

Gaffney, John ^{[1
]}

Matou-Nasri, Sabine ^{[1
]}

Grau-Olivares, Marta ^{[1
]}

Slevin, Mark ^{[1
]}

机构：

[1] Manchester Metropolitan Univ, Sch Biol Chem & Hlth Sci, Manchester M1 5GD, Lancs, England

来源：

MOLECULAR BIOSYSTEMS | 2010年 / 6卷 / 03期

关键词：

CEREBRAL-ARTERY OCCLUSION; CD44; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; BINDING PROTEINS; SPINAL-CORD; CELL-LINES; IN-VIVO; ACID; RAT;

D O I：

10.1039/b910552m

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Hyaluronan ( HA), a multifunctional, high molecular weight glycosaminoglycan, is a component of the majority of extracellular matrices. HA is synthesised in a unique manner by a family of hyaluronan synthases, degraded by hyaluronidases and exerts a biological effect by binding to families of cellular receptors, the hyaladhedrins. Receptor binding activates signal pathways in endothelial cells leading to proliferation, migration and differentiation collectively termed angiogenesis. HA and associated enzymes are implicated in the aetiology of cardiovascular disease and cancer and manipulation of HA expression offers a therapeutic target. HA microspheres have been developed as drug delivery agents to deliver HA to sites of disease and also in diagnosis. In this review we discuss some of the recent therapeutic applications of hyaluronan in tissue repair, as a drug delivery system and the synthesis, application and delivery of hyaluronan nanoparticles to target drugs to sites of disease.

引用

页码：437 / 443

页数：7

共 68 条

[1]

Hyaluronan expression following middle cerebral artery occlusion in the rat [J].

Al Qteishat, Ahmad ;

Gaffney, John J. ;

Krupinski, Jerzy ;

Slevin, Mark .

NEUROREPORT, 2006, 17 (11) :1111-1114

[2]

Changes in hyaluronan production and metabolism following ischaemic stroke in man [J].

Al'Qteishat, Ahmed ;

Gaffney, John ;

Krupinski, Jerzy ;

Rubio, Francisco ;

West, David ;

Kumar, Shant ;

Kumar, Patricia ;

Mitsios, Nicholas ;

Slevin, Mark .

BRAIN, 2006, 129 :2158-2176

[3]

Anttila MA, 2000, CANCER RES, V60, P150

[4]

Identification of CD44 residues important for hyaluronan binding and delineation of the binding site [J].

Bajorath, J ;

Greenfield, B ;

Munro, SB ;

Day, AJ ;

Aruffo, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) :338-343

[5]

Börjesson PKE, 2003, CLIN CANCER RES, V9, p3961S

[6]

Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate [J].

Cai, Shuang ;

Xie, Yumei ;

Bagby, Taryn R. ;

Cohen, Mark S. ;

Forrest, M. Laird .

JOURNAL OF SURGICAL RESEARCH, 2008, 147 (02) :247-252

[7]

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck [J].

Colnot, DR ;

Roos, JC ;

de Bree, R ;

Wilhelm, AJ ;

Kummer, JA ;

Hanft, G ;

Heider, KH ;

Stehle, G ;

Snow, GB ;

van Dongen, GAMS .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (09) :576-582

[8]

The six hyaluronidase-like genes in the human and mouse genomes [J].

Csoka, AB ;

Frost, GI ;

Stern, R .

MATRIX BIOLOGY, 2001, 20 (08) :499-508

[9]

The structure and regulation of hyaluronan-binding proteins [J].

Day, AJ .

BIOCHEMICAL SOCIETY TRANSACTIONS, 1999, 27 (02) :115-121

[10]

Hyaluronan-binding proteins: Tying up the giant [J].

Day, AJ ;

Prestwich, GD .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (07) :4585-4588

← 1 2 3 4 5 6 7 →